Ipsen ((GB:0MH6)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Ipsen is conducting a study titled ‘A Multicenter Non-interventional Study for the Measurement of Scratch and Sleep Patterns Using the ADAM Sensor in Patients With Primary Biliary Cholangitis.’ The study aims to objectively measure itching and sleep patterns in patients with Primary Biliary Cholangitis (PBC), a rare liver disease, using a digital health tool. This is significant as PBC patients often suffer from severe itching and sleep disturbances, impacting their quality of life.
Intervention/Treatment: The study uses a digital health tool, the ADAM sensor, to assess itchiness and sleep patterns in PBC patients. This non-invasive tool provides objective measurements, eliminating the need for patients to recall their symptoms.
Study Design: This is an observational cohort study with a prospective time perspective. It does not involve any allocation or masking, focusing instead on monitoring patients over a 91-day period to gather data on their symptoms.
Study Timeline: The study began on June 9, 2025, with the latest update on August 28, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status.
Market Implications: This study could positively impact Ipsen’s stock performance by showcasing their commitment to innovative solutions in rare diseases. As PBC is a niche market, advancements in treatment and symptom management could enhance Ipsen’s competitive edge and attract investor interest.
The study is currently ongoing, with further details available on the ClinicalTrials portal.